Search research articles
Contact Us
Filters
Showing results (61-70 of 71) with videos related to
Page
of 8
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 14, 2009
Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients
Daniel Podzamczer, Montserrat Olmo, Jose Sanz, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 29, 2009
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression
Esteban Martínez, José A Arranz, Daniel Podzamczer, et al.
The Journal of Antimicrobial Chemotherapy
|
March 7, 2019
Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice
Marta Alvarez, Paz Casas, Adolfo de Salazar, et al.
Ebiomedicine
|
April 19, 2021
Epigenome-wide association study of COVID-19 severity with respiratory failure
Manuel Castro de Moura, Veronica Davalos, Laura Planas-Serra, et al.
Biomedicines
|
March 28, 2025
Pharmacogenomic Study of SARS-CoV-2 Treatments: Identifying Polymorphisms Associated with Treatment Response in COVID-19 Patients
Alexandre Serra-Llovich, Natalia Cullell, Olalla Maroñas, et al.
Iscience
|
December 24, 2025
<i>OAS1</i> and <i>OAS3</i> genetic variants enhance inflammatory responses to SARS-CoV-2
Marta L DeDiego, Raúl López-Fernández-Sobrino, Jordi Pedragosa, et al.
Retrovirology
|
August 15, 2012
Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy
Gilberto Betancor, César Garriga, Maria C Puertas, et al.
Science (New York, N.Y.)
|
September 25, 2020
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Paul Bastard, Lindsey B Rosen, Qian Zhang, et al.
Research Square
|
January 19, 2022
The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies
Jeremy Manry, Paul Bastard, Adrian Gervais, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 16, 2022
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
Jérémy Manry, Paul Bastard, Adrian Gervais, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 71) with videos related to
Sort By:
Page
of 8
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 14, 2009
Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients
Daniel Podzamczer, Montserrat Olmo, Jose Sanz, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 29, 2009
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression
Esteban Martínez, José A Arranz, Daniel Podzamczer, et al.
The Journal of Antimicrobial Chemotherapy
|
March 7, 2019
Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice
Marta Alvarez, Paz Casas, Adolfo de Salazar, et al.
Ebiomedicine
|
April 19, 2021
Epigenome-wide association study of COVID-19 severity with respiratory failure
Manuel Castro de Moura, Veronica Davalos, Laura Planas-Serra, et al.
Biomedicines
|
March 28, 2025
Pharmacogenomic Study of SARS-CoV-2 Treatments: Identifying Polymorphisms Associated with Treatment Response in COVID-19 Patients
Alexandre Serra-Llovich, Natalia Cullell, Olalla Maroñas, et al.
Iscience
|
December 24, 2025
<i>OAS1</i> and <i>OAS3</i> genetic variants enhance inflammatory responses to SARS-CoV-2
Marta L DeDiego, Raúl López-Fernández-Sobrino, Jordi Pedragosa, et al.
Retrovirology
|
August 15, 2012
Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy
Gilberto Betancor, César Garriga, Maria C Puertas, et al.
Science (New York, N.Y.)
|
September 25, 2020
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Paul Bastard, Lindsey B Rosen, Qian Zhang, et al.
Research Square
|
January 19, 2022
The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies
Jeremy Manry, Paul Bastard, Adrian Gervais, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 16, 2022
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
Jérémy Manry, Paul Bastard, Adrian Gervais, et al.
Page
of 8